S
Exchange
—
Entity type
operating
Fiscal year end
Mar 31
Headquarters
Recent Filings
- 8-K208.4 KBSio Gene Therapies Inc.Apr 6, 4:06 PM ET·0001636050-23-000016
- 8-K202.1 KBSio Gene Therapies Inc.Mar 15, 4:25 PM ET·0001636050-23-000011
- 8-K370.1 KBSio Gene Therapies Inc.Feb 14, 7:01 AM ET·0001636050-23-000008
- 10-Q3.3 MBSio Gene Therapies Inc.Feb 14, 6:46 AM ET·0001636050-23-000007
- SC 13G/A107.1 KBSio Gene Therapies Inc.Feb 13, 8:53 AM ET·0000919574-23-000939
- SC 13G75.5 KBSio Gene Therapies Inc.Feb 10, 4:00 PM ET·0001104659-23-018477
- 8-K303.9 KBSio Gene Therapies Inc.Dec 14, 4:04 PM ET·0001636050-22-000054
- 8-K373.1 KBSio Gene Therapies Inc.Nov 10, 7:03 AM ET·0001636050-22-000051
- 10-Q3.4 MBSio Gene Therapies Inc.Nov 10, 7:02 AM ET·0001636050-22-000050
- 8-K188.2 KBSio Gene Therapies Inc.Sep 14, 4:08 PM ET·0001636050-22-000043
Insiders
10- Adasczik MichaelPrincipal Accounting Officer
- Altmeyer MarkPres&Chief Commercial Officer
- Bazley Mathew C.General Counsel
- Bickerstaff GeorgeDirector
- Cheruvu PavanChief Executive Officer
- Corcoran GavinEVP of R&D
- Cvijic Christine MikailChief Admin Officer and GC
- Dexcel Pharma Technologies Ltd.10% Owner
- Dexxon Holdings Ltd.10% Owner
- FALBERG KATHRYN EDirector
Tickers
No tickers on record
Addresses
business
1501 BROADWAY 12TH FLOOR
NEW YORK, NY, 10036
mailing
1501 BROADWAY 12TH FLOOR
NEW YORK, NY, 10036
Former Names
- Axovant Gene Therapies Ltd.2020-11-13
- Axovant Sciences Ltd.2019-04-18
- Roivant Neurosciences Ltd.2015-03-24